Functional Fluidics expands into Nigeria to help support sickle cell disease drug development and patient care.
Functional Fluidics, a biotechnology business based in the United States, has announced plans to expand into Nigeria in the fourth quarter of 2023.
Functional Fluidics has been providing a range of clinically validated assays to pharmaceutical companies and clinical providers across the United States for than a decade in order to support sickle cell disease new drug development and overall c.
Sickle cell disease is a hereditary illness that affects people all over the world. Each year, approximately 300,000 newborns are born with sickle cell disease (SCD) globally. With a high prevalence of SCD, Sub-Saharan African countries incur a considerable burden and play an essential role in the worldwide landscape of sickle cell disease.
“Functional Fluidics is taking a proactive approach, beginning in Nigeria in 2023, by establishing new operations in Sub-Saharan Africa.” We are committed to increasing access to valuable insights about red blood cell health that can be derived through our portfolio of red blood cell biomarkers. “Our goal at Functional Fluidics is to help Life Science innovators accelerate the speed, cost, and success rate of bringing new life-changing therapies to individuals with Sickle Cell Disease,” stated Dr. Patrick Hines, the company’s founder and CEO.
The company’s entrance into Nigeria comes after several years of strong growth and momentum as it aspires to be the gold standard for red blood cell health, beginning with sickle cell illness.
